1. Percentage of peripheral blood samples that demonstrated >5-fold in vitro expansion.
Percentage of peripheral blood samples that demonstrated >5-fold in vitro expansion. A, Samples from patients with solid tumors (Wilms tumor, neuroblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma) display low pass rates with CD3/CD28 stimulation, and this declines over time (X axis is cycle of chemotherapy, with 0 = diagnosis). B, Samples from patients with lymphoblastic or myeloid leukemia show high pass rates but also decline over time with each chemotherapy cycle. C, Line graph showing data from A/B with pass and indeterminate added together. D, Each individual disease type with pass rates over time. Asterisk indicates a significant decline over time (increasing number of chemotherapy cycles) by regression analysis (P < 0.05). N for each disease group is as in Table 1. See Supplementary Table S1 for summary of statistics for each disease compared with SR ALL.
Rajat K. Das et al. Cancer Discov 2019;9:
©2019 by American Association for Cancer Research